FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 6.8% in September

FibroGen, Inc. (NASDAQ:FGEN) saw a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 4,770,000 shares, a drop of 6.8% from the August 31st total of 5,120,000 shares. Based on an average daily volume of 2,180,000 shares, the short-interest ratio is presently 2.2 days.

Wall Street Analyst Weigh In

FGEN has been the topic of a number of recent analyst reports. StockNews.com initiated coverage on shares of FibroGen in a report on Friday. They set a “hold” rating on the stock. William Blair restated a “market perform” rating on shares of FibroGen in a report on Monday, June 3rd.

FibroGen Stock Down 3.6 %

Shares of FibroGen stock traded down $0.01 during trading on Tuesday, reaching $0.39. The company’s stock had a trading volume of 321,032 shares, compared to its average volume of 2,360,843. The business’s 50-day moving average price is $0.50 and its 200-day moving average price is $1.03. The firm has a market cap of $38.30 million, a PE ratio of -0.16 and a beta of 0.69. FibroGen has a 52 week low of $0.33 and a 52 week high of $2.93.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. The business had revenue of $50.64 million during the quarter, compared to the consensus estimate of $33.00 million. During the same period in the previous year, the firm posted ($0.65) EPS. Equities analysts predict that FibroGen will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On FibroGen

Several institutional investors and hedge funds have recently bought and sold shares of FGEN. Alpine Global Management LLC acquired a new position in FibroGen during the first quarter worth about $25,000. Delap Wealth Advisory LLC acquired a new position in shares of FibroGen in the first quarter valued at approximately $27,000. Accel Wealth Management acquired a new position in shares of FibroGen in the first quarter valued at approximately $103,000. Point72 DIFC Ltd increased its stake in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the period. Finally, Doheny Asset Management CA acquired a new position in shares of FibroGen in the second quarter valued at approximately $48,000. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.